Acambis Inc.

Sanofi Pasteur Biologics, LLC

Hookipa Biotech Gmbh

Sanofi Pasteur Biologics Co.

Oravax, Inc.

Oravax-merieux Co.

Ge Healthcare Bio-sciences Corp.

Other

Saint Louis University

Natural Environment Research Council

Emergent Product Development Gaithersburg Inc.

Pnuvax Inc.

Thomas P Monath

Farshad Guirakhoo

Konstantin V Pugachev

Juan Arroyo

William D Thomas, Jr

Katherine Cohen

Zhenxi Zhang

Wende Lei

Edward G Hayman

Richard A Weltzin

Cynthia K Lee

Klaus Orlinger

Gerhard Fuhrmann

Andreas Aspöck

John Avram Catalan

Elizabeth Watson

Paul J Giannasca

Bettina Kiefmann

Gopalan Soman

Vera Baumgartl-Strasser

Harold Kleanthous

Patrick M Guertin

Karen Lingnau

Michael Schwendinger

Sarah Schmidt

Anders Lilja

Charles Miller

Julia Hinteramskogler

J Jian Liu

Ursula Berka

Thomas J Chambers

Manuela Kainer

Bernhard Brim

Mario Aistleithner

Jacques Pappo

Katharina Bayer

Elsa Mühlbacher

William D Thomas

Jian Liu

James Scott Moncrief

David Maxwell Lyerly

Samuel K Ackerman

Polly Roy

Hitesh Bhagat

Richard D Nichols, Jr

Patricia Londono-Arcila

Donna Freeman

Thomas H Ermak

Ilene Sussman

Thomas Ermak

Francisco Javier Torres-Lopez

John A Catalan

Andreas ASPÖCK

Elsa MÜHLBACHER

Zhengi Zhang

Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.

CMV vaccines

Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.

HPV vaccines

The present application provides immunotherapies for Hepatitis B virus infections. Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of Hepatitis B virus infections. Also provided herein are pharmaceutical compositions and methods for the treatment of Hepatitis B virus infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating Hepatitis B virus infection.

Vaccines against hepatitis B virus

The invention provides flavivirus vaccines and methods of making and using these vaccines.

Flavivirus vaccines

The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.

High yield yellow fever virus strain with increased propagation in cells

The invention provides active and passive immunization methods for preventing and treatinginfection, which involve percutaneous administration oftoxin-neutralizing polyclonal immune globulin,toxoids, or combinations thereof. Also provided by the invention aretoxoids,toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that producetoxin-neutralizing polyclonal immune globulin.

[object Object]

The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses including attenuating mutations.

The invention provides attenuated Flavivirus vaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines.

Vaccines against japanese encephalitis virus and west nile virus

Recombinant flavivirus vaccines

The invention provides chimeric flavivirus vaccines against West Nile virus and methods of using these vaccines to prevent or treat West Nile virus infection.

West nile virus vaccine

The invention provides attenuatedvaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines.

Vaccines against Japanese encephalitis virus and West Nile virus

Growing community of inventors

Harvard, MA, United States of America

Thomas P Monath